SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIK, ACNB, PIRS, OBDE on Behalf of Shareholders

21.11.24 19:46 Uhr

Werte in diesem Artikel

NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

(PRNewsfoto/Halper Sadeh LLP) (PRNewsfoto/Halper Sadeh LLP)

Kidpik Corp. (NASDAQ: PIK)'s merger with Nina Footwear Corp. Upon closing of the proposed transaction, Nina's stockholders will own 80% of Kidpik's outstanding common stock. If you are a Kidpik shareholder, click here to learn more about your rights and options.

ACNB Corporation (NASDAQ: ACNB)'s merger with Traditions Bancorp, Inc. If you are an ACNB shareholder, click here to learn more about your rights and options.

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS)'s merger with Palvella Therapeutics, Inc. Pre-merger Pieris shareholders are expected to own approximately 18% of the combined company. If you are a Pieris shareholder, click here to learn more about your rights and options.

Blue Owl Capital Corporation III (NYSE: OBDE)'s merger with Blue Owl Capital Corporation. Under the terms of the proposed merger, OBDE shareholders will receive newly issued shares of OBDC for each share of OBDE based on an exchange ratio determined prior to closing. If you are an OBDE shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-pik-acnb-pirs-obde-on-behalf-of-shareholders-302313061.html

SOURCE Halper Sadeh LLP

Ausgewählte Hebelprodukte auf ACNB

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf ACNB

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Pieris Pharmaceuticals Inc

Analysen zu Pieris Pharmaceuticals Inc

DatumRatingAnalyst
16.01.2018Pieris Pharmaceuticals BuyH.C. Wainwright & Co.
30.05.2017Pieris Pharmaceuticals BuyRodman & Renshaw, LLC
27.07.2015Pieris Pharmaceuticals OutperformOppenheimer & Co. Inc.
22.07.2015Pieris Pharmaceuticals BuyROTH Capital Partners, LLC
DatumRatingAnalyst
16.01.2018Pieris Pharmaceuticals BuyH.C. Wainwright & Co.
30.05.2017Pieris Pharmaceuticals BuyRodman & Renshaw, LLC
27.07.2015Pieris Pharmaceuticals OutperformOppenheimer & Co. Inc.
22.07.2015Pieris Pharmaceuticals BuyROTH Capital Partners, LLC
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Pieris Pharmaceuticals Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"